Cargando…

Emerging drugs and combinations to treat multiple myeloma

In the past few years, multiple targeted therapies and immunotherapies including second generation immunomodulatory drugs (pomalidomide) and proteasome inhibitors (carfilzomib, ixazomib), monoclonal antibodies and checkpoint inhibitors were approved for the treatment of myeloma or entered advanced p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larocca, Alessandra, Mina, Roberto, Gay, Francesca, Bringhen, Sara, Boccadoro, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601169/ https://www.ncbi.nlm.nih.gov/pubmed/28948001 http://dx.doi.org/10.18632/oncotarget.19269

Ejemplares similares

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
por: D’Agostino, Mattia, et al.
Publicado: (2020)

Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients
por: Bonello, Francesca, et al.
Publicado: (2020)

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

New Strategies for the Treatment of Older Myeloma Patients
por: Larocca, Alessandra, et al.
Publicado: (2023)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Moving Toward Continuous Therapy in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
por: Bringhen, Sara, et al.
Publicado: (2018)

Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
por: D’Agostino, Mattia, et al.
Publicado: (2019)

Role of Allogeneic Transplantation in Multiple Myeloma in the Era of New Drugs
por: Bruno, Benedetto, et al.
Publicado: (2010)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
por: Musto, Pellegrino, et al.
Publicado: (2015)

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus
por: Mario, Boccadoro, et al.
Publicado: (2021)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Autologous transplant for myeloma: when the old meets the new
por: Gay, Francesca, et al.
Publicado: (2017)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2018)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Erratum: Mina, R.; et al. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. J. Clin. Med. 2020, 9, 2142
por: Mina, Roberto, et al.
Publicado: (2020)

Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
por: Bertuglia, Giuseppe, et al.
Publicado: (2022)

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
por: Larocca, Alessandra, et al.
Publicado: (2020)

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
por: Mina, Roberto, et al.
Publicado: (2021)

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
por: D’Agostino, Mattia, et al.
Publicado: (2021)

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
por: Montefusco, Vittorio, et al.
Publicado: (2020)

P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE
por: D’agostino, Mattia, et al.
Publicado: (2023)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
por: Bringhen, Sara, et al.
Publicado: (2020)

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
por: Saltarella, Ilaria, et al.
Publicado: (2019)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
por: Caers, Jo, et al.
Publicado: (2018)

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
por: Mian, Hira, et al.
Publicado: (2023)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
por: Gay, Francesca, et al.
Publicado: (2018)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
por: Chen, Wei-Chih, et al.
Publicado: (2017)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
por: Davis, Lorraine N., et al.
Publicado: (2021)

Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy
por: Bruno, Giulia, et al.
Publicado: (2019)

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2022)

Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients
por: Mingrone, Giulia, et al.
Publicado: (2021)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020)

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p4mbpq7bf4vhh2v4rbce0fi8gm